Literature DB >> 2957122

A receptor-antibody sandwich assay for teicoplanin.

A Corti, L Cavenaghi, E Giani, G Cassani.   

Abstract

We have developed a new method for quantifying teicoplanin in complex matrixes, a receptor-antibody sandwich assay (RASA). The method is based on bioselective adsorption of teicoplanin onto microtiter plates coated with albumin-epsilon-aminocaproyl-D-alanyl-D-alanine, a synthetic analog of its biological target, and reaction with anti-teicoplanin antibodies. The sandwich complexes are detected by incubation with peroxidase-labeled goat antibodies to rabbit IgGs and chromogenic reaction with o-phenylenediamine. The dose-response curve was linear for teicoplanin concentrations in the range from 0 to 0.15 mg/L. We used the assay to measure teicoplanin concentrations in various biological matrixes. Analytical recovery from serum was 99.5%, the interassay CV was 5.1%, and the detection limit was 30 micrograms/L (P less than 0.01). Mean analytical recoveries from other biological specimens were 98% from ascitic fluid, 100% from pleuric liquid, 104.8% from prostate homogenate, and 98.5% from bronchial expectorate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957122

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 2.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

3.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 4.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.